The conference was held in Moscow on the initiative of the Center for Healthcare Quality and Control of the Ministry of Health of the Russian Federation with the support of the Ministry of Health of the Russian Federation, Federation Council Committee on Social Policy, Federal Compulsory Health Insurance Fund, Health Technology Assessment Association and Autonomous Non-Profit Organization “National Center for Health Technology Assessment”.
The Conference provided the opportunity to discuss issues related to implementation of innovative health technologies including personalized medicine (gene and cell therapy, companion diagnostics) in the Russian Federation, and also improving approaches to health technology assessment.
Opening speech was delivered by Yuriy Arkharov, member of the Federation Council Committee. He pointed out the importance and relevance of the conference theme for improvement of healthcare worldwide. “It is clear that implementation of innovative technologies will facilitate higher quality of medical care. With rapid development of innovative technologies, health care costs also increase. Thus, the most adequate model for evaluation and selection of the most effective technologies is required”.
Timofey Nizhegorodtsev, Head of the Department for Control over Social Sphere and Commerce, Federal Anti-Monopoly Service, talked about main challenges of using innovative models of drugs provision in Russia explaining that agreement should be performed on the basis of unified rules, requirements, documents samples produced and endorsed by the Ministry of Health of the Russian Federation.
Vitaly Omelyanovskiy, General Director of the Center for Healthcare Qaulity Assessment and Control of the Ministry of Health of the Russian Federation noted: “Blockbuster medicine, i.e. when a drug was extremely popular generating huge sales and administered to many patients, has been moving toward personalized medicine meaning that standard treatment approaches are being replaced by the treatment of a particular patient. Molecular diagnostics market is growing significantly due to oncology and genetic studies, thus, in terms of personalized medicine therapeutic drugs effectiveness becomes more and more dependent on specific biomarkers. Effective use of target therapy is possible only if appropriate molecular genetics research is conducted. Speaking of HTA in Russia it is important to note that willingness-to-pay threshold should be defined, which would contribute to transparency of decision-making, and also help make certain decisions on assessing approaches to identify therapeutic value of new technologies and introduce new HTA mechanisms for biomedical cell products and medical devices”.
International experts participated in the Conference and shared their experience in innovative therapies, approaches to applying gene therapy, advanced therapy medicinal products, comprehensive genomic profiling in Precision Medicine, evaluation of NGS medical services in healthcare systems in the European Union. The invited experts were: Stefan Vranckx – Chief of the International Department of the European Federation of Pharmaceutical Industries and Associations (EFPIA); Francesco Testa – MD, PhD, IRD specialist, Associate Professor of Ophthalmology, School of Medicine, University of Campania Luigi Vanvitelli, Maarten Kempen – Clinical Sales Director Reproductive & Genetic Health Europe, Middle East & Africa for Illumina and other foreign experts.
At the end of the Conference a resolution was signed, which contained proposals on gene and cell therapy technologies implementation in the health care system and further development of HTA system in the Russian Federation.